DJIA 16,408.54 -16.31 -0.10%
NASDAQ 4,095.52 0.00 0.00%
S&P 500 1,864.85 2.54 0.14%
market minute promo


company name or ticker

Stem Cells: Invest At Your Own Peril

Stocks Hitting 52-Week Lows

Investing In The Stem Cell Sector: An Overview

Companies That Can Mend The Biotech Market: Stephen Brozak

Aastrom Biosciences Says First Patients Enrolled in ixCELL-DCM Phase 2b Clinical Trial of Ixmyelocel

Aastrom Biosciences Says First Patients Enrolled in ixCELL-DCM Phase 2b Clinical Trial of Ixmyelocel-T

Stocks Hitting 52-Week Lows

Benzinga's Top Downgrades

Market Close: Big Winners & Losers for March 27, 2013 (CHCI, RDHL, UEPS, RVLT, LIVE, ASTM, EVBS, ISN

Market Close: Big Winners & Losers for March 27, 2013 (CHCI, RDHL, UEPS, RVLT, LIVE, ASTM, EVBS, ISNS, ATOS, GV)

Oppenheimer Reiterates Perform Rating on Aastrom Biosciences on Discontinuation of Phase III REVIVE

Oppenheimer Reiterates Perform Rating on Aastrom Biosciences on Discontinuation of Phase III REVIVE CLI

Aastrom's Shocking News And Future Potential

See More Articles...